Document Type
Article
Publication Date
2025
Abstract
Diabetes is a chronic metabolic disease with high morbidity and mortality due to its complications. Recently, there has been growing interest in identifying new bioactive compounds, including marinederived secondary metabolites, for potential antidiabetic activities. This study focuses on secondary metabolites from marine sponges from the genus Dysidea that show strong inhibition of protein tyrosine phosphatase 1B (PTP1B), a key target in antidiabetic therapy. Thirteen out of the thirty-one compounds were identified to have promising in silico potentials vs PTP1B: avarol (1), avarone (2), furodysin (3), nakafuran 8 (4), haterumadysin A (5), pyrodysinoic acid (6), avinosol (7), puupehenone (8), α-santonin (9), 4’-methylaminoavarone (10), 3’-methylaminoavarone (11), diplopuupehenone (12), and dysideanin B (13). Among these, 12 showed the highest binding energy (-7.9 kcal/mol). All 13 compounds were predicted to have a favorable drug-likeness and pharmacokinetic profile, except compounds 7 and 12. These computational findings suggest that secondary metabolites from the marine sponge Dysidea, particularly those with strong binding affinities and good drug-like properties, could serve as promising candidates for developing new generation anti-diabetic drugs and further in vitro confirmatory tests.
Recommended Citation
Lasam, G. A., Aguila, M. N., De Jesus, A. J., Guzman, G. G., Jontillano, V. J., Manzano, J. A., Ramos, J. D., & Rondolo, I. B. (2025). PTP1B Inhibitors of Marine Sponge-Derived Secondary Metabolites from Dysidea. Acta Manilana, 73, 52-66. https://archium.ateneo.edu/
